ライフサイエンスコーパス: cell-based assay

1 d, primary mutations were identified using a cell-based assay.

2 A mutations impaired transport activity in a cell-based assay.

3 e-activated cell sorting, a live transfected cell-based assay.

4 rgenic functionality was then assessed using cell-based assay.

5 rse chemical structures was screened using a cell-based assay.

6 ovided an acceptable detection limit for the cell-based assay.

7 4 muM and inhibited tau phosphorylation in a cell-based assay.

8 a Ki of 0.7 microM and showed activity in a cell-based assay.

9 ility of Gli1 to activate Has2 promoter in a cell-based assay.

10 similarity and the top drugs evaluated in a cell-based assay.

11 ctron reduction assays as well as in a HaCaT cell-based assay.

12 ed phosphorylation of the EphA4 protein in a cell-based assay.

13 Tau prions were measured using a cell-based assay.

14 ompounds in complex natural mixtures using a cell-based assay.

15 he mouse neutralization assay and a neuronal cell-based assay.

16 hod; and LRP4 antibodies were tested using a cell-based assay.

17 on of H3K9Me3 and H3K4Me3 demethylation in a cell-based assay.

18 one mAbs revealed inhibitory properties in a cell-based assay.

19 it nanomolar potency in both biochemical and cell based assays.

20 s and in shorter time span than conventional cell based assays.

21 ation (pAKT) in PI3Kdelta-dependent in vitro cell based assays.

22 t also apply to drug studies with other stem cell-based assays.

23 e of antibodies to AQP4, MOG, and GlyR using cell-based assays.

24 , correlates directly with their efficacy in cell-based assays.

25 heir reported loss-of-function phenotypes in cell-based assays.

26 tly (IC50 < 100 nm) inhibit Jak3 activity in cell-based assays.

27 zers, which was confirmed experimentally via cell-based assays.

28 antibody positivity, which was confirmed by cell-based assays.

29 against HIV-1ADA-M, HSV-2, and HPV16 PsV in cell-based assays.

30 oteases cathepsins and renin and activity in cell-based assays.

31 g and reduce prion levels was established in cell-based assays.

32 ere further characterized in biochemical and cell-based assays.

33 the absence of the activating EGF ligand in cell-based assays.

34 DA from serum samples prior to conduction of cell-based assays.

35 usogenicity and Shiga toxin Vero toxicity in cell-based assays.

36 in vitro and to impair viral replication in cell-based assays.

37 inst HIV-1 vectors harboring wild-type IN in cell-based assays.

38 rformed using brain immunohistochemistry and cell-based assays.

39 of which cannot be adequately assessed with cell-based assays.

40 RNA packaging to a DeltaNC HIV-1 variant in cell-based assays.

41 lar concentrations, with minimal toxicity in cell-based assays.

42 urther studied for antigen specificity using cell-based assays.

43 lity of the targeted agent were confirmed in cell-based assays.

44 in enzymatic assays and viral replication in cell-based assays.

45 n MIC(9)(0) of 0.7 mug/mL for this fungus in cell-based assays.

46 ar concentrations against the three GPCRs in cell-based assays.

47 domains that neutralize Stx1 and/or Stx2 in cell-based assays.

48 inant enzymes (RNase H and integrase) and in cell-based assays.

49 n vitro cleavage assay, and several neuronal cell-based assays.

50 analyzed using a combination of in vitro and cell-based assays.

51 ll fermentation, cell fate reprogramming and cell-based assays.

52 combination of biochemical, biophysical, and cell-based assays.

53 f-rate was evaluated by gel filtration and T cell-based assays.

54 the mechanism of truncation in cell-free and cell-based assays.

55 e cellular p53 and to inhibit cell growth in cell-based assays.

56 ng locus sufficient for enhancer activity in cell-based assays.

57 luated in vitro using recombinant enzyme and cell-based assays.

58 involvement in genome maintenance using two cell-based assays.

59 y, which we demonstrate biochemically and in cell-based assays.

60 characterized using different approaches and cell-based assays.

61 efficient end joining and radioresistance in cell-based assays.

62 ns the development of specific and sensitive cell-based assays.

63 A receptor, and the AMPA receptor using live cell-based assays.

64 , many of which had bactericidal activity in cell-based assays.

65 further characterized using biochemical and cell-based assays.

66 le variants of EBOV and other filoviruses in cell-based assays.

67 l four serotypes with low micromolar EC50 in cell-based assays.

68 ce the induction and dynamics of vimentin in cell-based assays.

69 ase models at the speed and cost of in vitro cell-based assays.

70 ormation and attenuate virion infectivity in cell-based assays.

71 situ hybridization, immunohistochemistry and cell-based assays.

72 nd can be activated specifically by NPY-8 in cell-based assays.

73 l-based assay (1.5%), and in CSF controls by cell-based assay (0.9%).

74 rum controls by tissue-based assay (0.5%) or cell-based assay (1.5%), and in CSF controls by cell-bas

75 In cell-based assays, 1.0 nM of Pz-1 strongly inhibited pho

76 In cell-based assays, ACY-738 increased the relative associ

77 Combining NMR with cell-based assays allowed us to differentiate defects in

78 Cell-based assays also indicate that bVP24 exhibits decr

79 ing in silico computational models, in vitro cell based assays and in vivo biodistribution studies.

80 Here, we used a cell-based assay and automated immunofluorescence micros

81 Our results demonstrate that the cell-based assay and GO enzyme assay developed in this s

82 partate receptor using a flow cytometry live cell-based assay and immunolabeling of murine primary ne

83 cosylation significantly decreased ADCC in a cell-based assay and suppressed antibody-mediated cell k

84 e ability of each mutant to bind RetGC1 in a cell-based assay and to activate it in vitro.

85 ve similarly to ZMC1 in both biophysical and cell-based assays and are heretofore named ZMC2 (NSC3197

86 Using cell-based assays and brain slice preparations, we chara

87 We show here, through cell-based assays and cell-specific gene deletion experi

88 their biologic properties were determined in cell-based assays and confocal microscopy.

89 o increased cell-cell adhesion in functional cell-based assays and disruption of cell polarity in a t

90 e highly useful bioluminescent reporters for cell-based assays and drug discovery.

91 repression by Pumilio and Nanos, we created cell-based assays and found that Pumilio inhibits transl

92 We validate this approach in cell-based assays and in a mouse model of TCR gene trans

93 The lead compound had activity in cell-based assays and in a mouse xenograft efficacy mode

94 nists of TLRs 7, 8 and 9 in murine and human cell-based assays and in vivo in mice and non-human prim

95 pool of the two-component monomers tested in cell-based assays and in vivo mouse models.

96 to be an allosteric agonist, active in both cell-based assays and in vivo.

97 However, using cell-based assays and integrated proteomics, phosphoprot

98 s showed potent IC50 values in enzymatic and cell-based assays and significant intraocular pressure (

99 This includes functional cell-based assays and the evaluation of molecular expres

100 annel blocking ability were determined using cell-based assays and two-electrode voltage clamp (TEVC)

101 Cell-based assays and unique strain devices were used to

102 ar or low micromolar range in enzyme- and/or cell-based assays and with high therapeutic indices.

103 nd Mycbp positively regulate Hh signaling in cell-based assays and zebrafish.

104 sing immunoprecipitation, mass spectrometry, cell-based assay, and analysis of antibody effects in cu

105 ed for hGLUT family members, hGLUT1-4, using cell-based assays, and compared with homology models for

106 ch, including clinical analysis of patients, cell-based assays, and computational studies, we charact

107 nerve and isolated airway neuron tissue- and cell-based assays, and in vivo single-fiber recording el

108 AT3 with selectivity over STAT5 and STAT1 in cell-based assays, and increases the apoptotic rate of c

109 4A9, as quantified via ELISA, hemolytic, and cell-based assays, and showed improved solubility, as me

110 ship (SAR) studies utilizing biochemical and cell-based assays, and structure-based drug design is re

111 AP isoforms (alpha, varepsilon, or kappa) by cell-based assays; and (3) clinical data available.

112 This cell-based assay approach can be used for several other

113 We present a high content multiwell plate cell-based assay approach to quantify protein interactio

114 llular bar-code technology in which multiple cell-based assays are combined in one well after which e

115 t aspect of mathematical models as in vitro, cell-based assays are expected to provide the bulk of ex

116 nterest in the HIV vaccine field but current cell-based assays are usually difficult to reproduce acr

117 Here, we use a combination of cell-based assays, biophysical analysis, and atomic forc

118 HIF-1 pathway inhibitor in a high-throughput cell-based assay, but its in vivo delivery is hampered b

119 r all of these possibilities in vitro and in cell-based assays, but moving RET into intact animals ha

120 tants in a cellular milieu, we established a cell-based assay by stably expressing 2 reporter protein

121 Together these data suggest that cell based assays can reveal subtle but clinically relev

122 This novel cell-based assay can predict either protective or detrim

123 we are introducing a new platform to realize cell-based assay capable of increased throughput and gre

124 or CHK1 potency and high selectivity using a cell-based assay cascade.

125 orbent assay (ELISA) and a fixed transfected cell-based assay (CBA), we tested AQP4-IgG in a northern

126 , we used rat brain immunohistochemistry and cell-based assays (CBA) with fixed or live NMDA receptor

127 Cell-based assays (CBAs) were shown to improve detection

128 intracellular delivery should be useful for cell-based assays, cellular imaging applications and the

129 However, resulting candidate gene lists from cell-based assays comprise diverse effectors, both direc

130 Cell-based assays confirm that the pericellular hydrogel

131 A cell-based assay confirmed that all 4 patients, but not

132 Cell-based assays confirmed this hypothesis, linking the

133 Cell-based assays corroborated these findings in mice.

134 itional repair function of NONO, revealed in cell-based assays, could involve RNA interaction.

135 We then successfully applied our approach on cell-based assay data and on tissue images.

136 Complementary cell-based assays demonstrate a DNA-damage-induced p53-S

137 ro lipid/membrane binding assays and in vivo cell-based assays demonstrate that mutagenesis of Asp370

138 Moreover, single-cell-based assays demonstrate that treatment with TPPU r

139 Cell based assays demonstrated that the optimized inhibi

140 Cell-based assays demonstrated that HUWE1 interacts with

141 Furthermore, cell-based assays demonstrated that some of the caffeine

142 alidate mitoxantrone in orthogonal mammalian cell-based assays, demonstrating that our screening appr

143 cted in Dominica showed strong activity in a cell-based assay designed to detect antagonists of the a

144 In addition, most functional cell-based assays designed to characterize the neutraliz

145 in the fusion scaffold was not active in the cell-based assay due to the N-terminal degradation.

146 It is anticipated that other fast-response cell-based assays (e.g., other ion flux assays) can be i

147 ts S1P-induced receptor internalization in a cell-based assay (EC50 = 0.05 muM), but has poor physica

148 In cell-based assays, either hepcidin from hepatocytes or e

149 These cell-based assays elucidate this important aspect of tra

150 We have used an established cell-based assay employing a PC12 cell line overexpressi

151 in to test this hypothesis we utilised human cell-based assays, ex vivo murine BALF, in vivo pre-clin

152 In recent years, in vitro cell-based assays, ex vivo palate cultures, and genetica

153 Although cell-based assays exist, rapid and cost-efficient high-c

154 ug Administration-approved drugs, in a novel cell-based assay, followed by secondary screens in brain

155 ass spectrometry-based high-throughput whole cell-based assay for aldosterone synthesis.

156 Thereby a complete cell-based assay for efficient drug screening is perform

157 resent study, a high-throughput, functional, cell-based assay for identifying Maxi-K channel agonists

158 We have established an NK-92 cell-based assay for IFN-gamma release, identified resid

159 screen of a human miRNA mimetic library in a cell-based assay for invasion by the melanoma cell line

160 Using a cell-based assay for RNA synthesis by the RNA-dependent

161 hable kinases, we established an all-optical cell-based assay for screening inhibitors, uncovered a d

162 ough heterologous expression of receptors in cell-based assays for 9 endogenous ligands.

163 The other two patients tested negative by cell-based assays for all known CNS antigens.

164 Cell-based assays for all other known CNS antigens were

165 ished atlastin1/SPG3A disease variants using cell-based assays for atlastin-mediated ER network forma

166 enomenon of glyco-stress provides convenient cell-based assays for developing a new class of inhibito

167 e National Cancer Center were analysed using cell-based assays for MOG-IgG and aquaporin-4 immunoglob

168 excitotoxicity, hindering the development of cell-based assays for NMDAR drug discovery.

169 vitro assays, including enzymatic tests and cell-based assays for viral replication and cellular gro

170 ng sites on G protein-coupled receptors in a cell-based assay format.

171 o penetrate cell membranes effectively, this cell-based assay has the potential to serve as a useful

172 Humoral-based and cell-based assays have identified antibodies against mye

173 ion scheme, ensemble docking, and innovative cell-based assays, here we show that andrographolide (AG

174 Moreover, biochemical and cell-based assays identify oxidative stress as a signall

175 Higher density 384-well cell-based assays illustrated the kinetics of enzyme ina

176 pectrometry, and subsequently confirmed with cell-based assays, immunohistochemistry with teased rat

177 g of the endogenous LGI4 transcript and in a cell-based assay impaired the secretion of truncated LGI

178 vity, and provides an important standardized cell-based assay in the field.

179 PR-mediated loss-of-function screens using a cell-based assay in which mitosis is consistently distur

180 with first-episode psychosis using classical cell-based assays in three labs and a single molecule-ba

181 was corroborated in vitro by embryonic stem cell-based assays in which we showed that the overexpres

182 mined the function of these structures using cell-based assays, in vitro translation systems, and in

183 nvestigated ghrelin signaling in a number of cell-based assays, including Ca(2+) mobilization, serum

184 ryptic inhibited ligand signaling in various cell-based assays, including SMAD-mediated luciferase re

185 Biophysical analyses in combination with cell-based assays indicate that hRpn13 binds preferentia

186 Both cell-free and cell-based assays indicate that the A420P mutation aboli

187 Initial cell-based assays indicated that MCP-1(T10C) could activ

188 Cell-based assays indicated that the hydrolysates presen

189 Further evaluation using cell-based assays, indirectly linked to galectin-3 inhib

190 interacting ArfGAP 1) gene using functional cell-based assays involving coexpression of GIT1 and PAK

191 Cell-based assay is a useful procedure in the routine di

192 sting all potentially mutagenic compounds in cell-based assays is tedious and costly.

193 utations obtained using a recently validated cell-based assay (J Thromb Haemost 11(5):872).

194 ves was synthesized, and SAR analysis, using cell-based assays, led to the discovery of 28 (AMG 925),

195 Cell-based assays, like the cellular antioxidant activit

196 However, its relatively high EC(50) in cell based assays, low lipophilicity, high topological p

197 In cell-based assays, low concentrations of actinomycin D p

198 In cell-based assays, matriptase was a potent activator of

199 vitro and that ago-PAM activity observed in cell-based assays may not be important for in vivo effic

200 AZD6738, we have developed multi-parametric cell based assays measuring DNA damage and cell cycle tr

201 sing 21 assays including live (n=3) or fixed cell-based assays (n=10), flow cytometry (n=4), immunohi

202 Proteasome-Glo is a homogeneous cell-based assay of proteasomal chymotrypsin-like, tryps

203 Cell-based assays of BBB permeation, neurotoxicity, and

204 creased potency in kinase, thermal shift, or cell-based assays of BMP signaling and transcription, as

205 We found that functional cell-based assays of three point mutants affecting resid

206 Cell-based assays of tubulin dynamics reveal various eff

207 tion of dengue and West Nile virus titers in cell-based assays of virus replication, with an EC50 val

208 Through cell-based assays on several human-derived cell lines, w

209 -tetramethylindocarbocyanine perchlorate LDL cell-based assays on the stable knockdown HepG2 and Huh7

210 Cell-based assays play a critical role in discovery of n

211 Using live cell-based assays, Positive and Low Positive antibodies

212 showed dose-dependent inhibition of SOCE in cell-based assay, probably through interacting with the

213 dentified one residue (position 170) that in cell-based assays profoundly altered pathway selectivity

214 Label-free approaches to monitor cell-based assays provide an unprecedented, time-resolve

215 istinct clinical phenotypes; the established cell-based assay provides a powerful tool for studying t

216 rement of the rate of the self-assembly in a cell-based assay provides precise assessment of the cell

217 This model is further supported by cell-based assay results using dsRNA ligands of lengths

218 Cell-based assays revealed subtly distinct intracellular

219 In vitro and cell-based assays revealed that the CNAbeta1-containing

220 We report here an approach that combines a cell-based assay's quantitative accuracy and direct rela

221 Cell-based assays show that expression of full-length HP

222 Our biophysical and cell-based assays show that the secondary interface cont

223 Cell-based assays showed that CacyBP/SIP forms a homodim

224 Despite significant progresses, cell-based assays still have major limitations part to b

225 23 muM against Mycobacterium tuberculosis in cell-based assays, suggesting that these compounds are t

226 el recombinant LCMV and its use to develop a cell-based assay suitable for HTS to rapidly identify in

227 Cell-based assay supports the physiological relevance of

228 They use this cell-based assay system to help explain the clinical man

229 ose studies relied on cell-free or accessory cell-based assay systems that do not accurately reflect

230 and exhibits higher inhibitory activities in cell-based assays than biochemical assays.

231 To measure the toxin activity, we used a cell based assay that makes quantification more robust a

232 We have developed a human cell-based assay that monitors IFN-beta production for u

233 Using a cell-based assay that recognizes microtubule polymerizat

234 We have developed a microscale cell-based assay that responds to complex pro- and antia

235 PAPP-A cleavage of IGFBP-4, and we show in a cell-based assay that STC1 effectively antagonizes PAPP-

236 We demonstrate using cell-based assays that an Ang2 chimera containing the An

237 This result underscores the importance of cell-based assays that capture chemical cross-talk occur

238 Traditional methods rely on cell-based assays that lack reproducibility and accuracy

239 ultidisciplinary development of in vitro and cell-based assays that more appropriately reflect the ph

240 There is a lack of rapid cell-based assays that read out enzymatic inhibition of

241 Nonetheless, in cell-based assays the Sestd1-Dact1 interaction can induc

242 on-coding region we have further developed a cell-based assay (the 3'CRE-REP assay) to yield recombin

243 In HEK293, mouse and human cell-based assays, the antagonist compounds inhibited si

244 In cell-based assays, the compounds show growth inhibition

245 In CME and growth inhibition cell-based assays, the data obtained was consistent with

246 surface of beads, and increase uniformity in cell-based assays through automation.

247 Finally, we developed a DropArray cell-based assay to evaluate a bispecific antibody desig

248 We devised a high-throughput, cell-based assay to identify compounds to treat Group3 m

249 Here we describe a reporter cell-based assay to quantify inducible, replication-comp

250 Cell-based assays to assess the effect of ADH-41 on Abet

251 X-ray crystallography, NMR spectroscopy, and cell-based assays to demonstrate that recruitment and ph

252 We also used a variety of cell-based assays to dissect the specific step of the HC

253 These findings were supported by in vitro cell-based assays to evaluate cell viability, induction

254 We tested all four TSCs in a number of cell-based assays to examine mutant p53 reactivation and

255 tibody detection should be supplemented with cell-based assays to examine the correlations between th

256 In this study, we used cell-based assays to examine the effect of two CA bindin

257 response performance and off-target effects, cell-based assays to identify compounds that attenuate V

258 We used surface plasmon resonance and cell-based assays to investigate this important IFN-beta

259 We employed a combination of cell-free and cell-based assays to shed light on the underlying molecu

260 owing that the unique responses of different cell-based assays to specific drugs are retained when th

261 chemistry using live hippocampal neurons and cell-based assays to test for anti-N-methyl-d-aspartate

262 uctural analysis, as well as biophysical and cell-based assays, to show that the DEP domain of Dishev

263 Using biochemical and cell-based assays together with mutagenesis, we show tha

264 Here, we report the development of a cell-based assay used with a library of human miRNA mimi

265 ere comprehensively tested for NSA-abs, with cell-based assays used for leucine-rich glioma-inactivat

266 y offers a unique avenue to produce in vitro cell-based assays useful for developing new anticancer t

267 Here we describe a cell-based assay using patient cell lines to identify sm

268 assay, and selectively inhibited SOAT1 in a cell-based assay using SOAT1-/SOAT2-CHO cells.

269 Cell-based assays using C-terminal-truncated human MOG a

270 ely 1 muM and selectivity indices of >100 in cell-based assays using western equine encephalitis viru

271 However, some heterogeneity between cell-based assays was clearly observed, highlighting the

272 nst norovirus 3C-like protease in enzyme and cell-based assays was determined.

273 Using cell-based assays we show that metitepine is an antagoni

274 Using diseased chondrocytes and a cell-based assay, we determined that these mutations sel

275 Using a cell-based assay, we found that TNAP rapidly hydrolyzed

276 Using an epithelial cell-based assay, we showed that immobilized S.Typhimuri

277 nding and imaging as well as biochemical and cell-based assays, we demonstrated that ZCL278 has emerg

278 hrough structure-based virtual screening and cell-based assays, we discovered a novel small molecule

279 of bioinformatics, biochemical analysis, and cell-based assays, we identify here specific histone mod

280 Combining in vitro reconstitution and cell-based assays, we now identify dual mechanisms throu

281 Using cell-based assays, we show here that PIs can directly in

282 Using in vitro and cell-based assays, we show that Nek2 phosphorylates the

283 ynamics simulations, biochemical assays, and cell-based assays, we showed that the mutation is a bona

284 onfirmed that the drugs identified using the cell-based assay were all acting at the receptor level b

285 Positive or Low Positive by the Oxford live cell-based assay were reviewed.

286 The cell-based assays were most sensitive and specific overa

287 ompounds with high activity in cell-free and cell-based assays were obtained.

288 on rat brain and cultured neurons as well as cell-based assays were used to identify known autoantibo

289 e, a bridging ELISA, as well as a functional cell-based assay, were constructed.

290 We introduce a single-cell-based assay which allows us to control how fast the

291 125)I-alphaDTX-labelled Kv1 subunits, and by cell-based assays which expressed Kv1 subunits, LGI1 and

292 d well with those from mass spectrometry and cell-based assay, which are the industrial standards for

293 most potent inhibitors were also tested in a cell-based assay, which demonstrated that they effective

294 igh inhibitory potency in both enzymatic and cell-based assays while preserving the appealing selecti

295 and 5 kDa showed an inhibitory effect in the cell-based assay, while the fraction containing molecule

296 ling through G protein-dependent pathways in cell-based assays, while CXCL12-gamma had greatest effec

297 Cell-based assay with HEK293 expressing alpha1/beta3 sub

298 ed by automated fluorescence microscopy in a cell-based assay with murine macrophages.

299 e with rat hippocampal neuronal cultures and cell-based assays with known neuronal cell-surface antig

300 SHMT in target assays and PfNF54 strains in cell-based assays with values in the low nanomolar range